Revvity Inc. Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 3, 2026 results vs estimates
Revvity Inc. Forecast
Revvity Inc. short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.9% a year, a typical one-standard-deviation range is 159.74–171.82 over a week, 153.40–178.16 over a month and 122.88–208.68 over a year. (Signals as of 1 Nov 2026.)
Revvity Inc. Price Chart
Revvity Inc. Factors
YoY +51.3%
YoY +53.2%
YoY +62.5%
YoY +44.5%
YoY +41.4%
YoY −25.8%
YoY −33.9%
YoY −41.3%
YoY +60.2%
YoY −10.9%
YoY −12.9%
YoY +51.3%
YoY +45.5%
YoY +2.7%
YoY −16.7%
YoY +33.3%
YoY +51.0%
Revvity Inc. fundamentals: income statement, balance sheet & cash flow
Revvity Inc. reported revenue of $2.86bn and net income of $241.7m in FY2025, the year ended 31 December 2025 — revenue up 3.7% and net income down 18.3% on the prior year. Free cash flow was $508.3m. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 81 FINRA short-interest settlements are published alongside them, back to May 2023.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 2,856.1 | 2,755.0 | 2,750.6 | 3,311.8 | 3,827.8 |
| Cost of revenue | 1,340.0 | 1,432.4 | 1,428.4 | 1,551.1 | 1,545.9 |
| Gross profit | 1,516.1 | 1,322.7 | 1,322.2 | 1,760.7 | 2,282.0 |
| Research & development | 215.8 | 196.8 | 216.6 | 221.6 | 200.3 |
| Operating income | 356.6 | 410.5 | 399.5 | 781.1 | 1,340.0 |
| EBITDA | 765.8 | 840.3 | 713.6 | 1,182.8 | 1,617.2 |
| Interest expense | 92.2 | 96.3 | 98.8 | 104.0 | 102.1 |
| Pre-tax income | 268.3 | 316.1 | 183.0 | 651.8 | 1,203.6 |
| Income tax | 25.8 | 33.1 | 3.5 | 139.2 | 314.1 |
| Net income | 241.7 | 295.8 | -118.4 | 569.2 | 943.2 |
Download Revvity Inc. fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.RVTY.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Revvity Inc.
Explore MacroFinance macro & markets research and analysis.
Revvity Inc. Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Revvity Inc.; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Revvity Inc.’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Revvity Inc. (United States)
Revvity Inc. is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Revvity Inc.?
What is the latest Revvity Inc. price?
Is Revvity Inc. in an uptrend?
How volatile is Revvity Inc.?
What factors affect Revvity Inc.?
Which trading strategies trade Revvity Inc.?
How are Revvity Inc. returns analysed?
Where can I download free Revvity Inc. historical data?
Free Revvity Inc. historical data (last 10 years)
Browse or instantly download the last 10 years of Revvity Inc. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.RVTY.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 145.22 |
| 2026-11-19 | 151.59 |
| 2026-11-18 | 152.43 |
| 2026-11-17 | 147.79 |
| 2026-11-16 | 148.85 |
| 2026-11-13 | 154.39 |
| 2026-11-12 | 157.02 |
| 2026-11-11 | 158.25 |
| 2026-11-10 | 159.1 |
| 2026-11-09 | 160.72 |
About this stock
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.